Announcements Trials

Browse Landscape

Phase

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Venous Thromboembolism 10 Pulmonary Embolism 4 Venous Thrombosis 3 Neoplasms 3 Thrombosis 2 Multiple Myeloma 2 Urinary Bladder Neoplasms 1 Thromboprophylaxis 1 Thromboembolism 1 Thrombocytopenia 1 Neoplasms, Plasma Cell 1 Lymphoma 1 Leukemia 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Glioma 1 Glioblastoma 1 Fibrosis 1 Embolism 1 Carcinoma, Hepatocellular 1 Astrocytoma 1

Interventions

Gemcitabine 56 pembrolizumab 50 Cisplatin 43 Magnetic Resonance Spectroscopy 27 enfortumab vedotin 22 Specimen Handling 22 Nivolumab 22 Cystectomy 18 durvalumab 16 Carboplatin 16 avelumab 15 Mitomycin 14 atezolizumab 13 Docetaxel 13 Cystoscopy 12 Fluorouracil 11 Radiation 9 Transurethral Resection of Bladder 8 Radiotherapy 8 Ipilimumab 8 sacituzumab govitecan 7 Standard of Care 7 Radiosurgery 7 Paclitaxel 7 Immunoglobulin G 7 Disulfides 7 erdafitinib 6 cemiplimab 6 Surveys and Questionnaires 6 Surgical Procedures, Operative 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Urinary Bladder Neoplasms × apixaban × 1 year × Clear all

NCT06243510 2026-01-28

CARE

Abramson Cancer Center at Penn Medicine

Phase NA Enrolling by invitation

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡